Showing 1196 results
- Media Release /Patient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social…
- Media Release /Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
- Media Release /Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
- Media Release /Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off…
- Media Release /Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le…
- Media Release /Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer…
- Media Release /Der Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%…
- Media Release /US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…
- Media Release /Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…
- Media Release /After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase…
Pagination
- ‹ Previous page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- …
- 120
- › Next page